ArticleCureus2025
Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic hydrothorax presents a significant challenge in advanced liver cirrhosis management, especially when conventional therapies fail. We report a case of a 66-year-old male with hepatitis C-related cirrhosis and advanced hepatocellular carcinoma who developed refractory left-sided hepatic hydrothorax despite maximal diuretic therapy. After failed talc pleurodesis, we employed an alternative approach using 50% glucose solution as a sclerosing agent. Following three sessions of hypertonic glucose pleurodesis, the patient achieved sustained resolution of pleural effusion with only minor, transient complications including hypotension and mild inflammatory response. Notably, he did not develop significant renal dysfunction or hepatic decompensation, complications commonly associated with conventional sclerosing agents in liver cirrhosis. Two-month follow-up imaging confirmed persistent pleural adhesion. This case highlights hypertonic glucose pleurodesis as a potentially safer alternative for managing refractory hepatic hydrothorax, particularly in patients unsuitable for transjugular intrahepatic portosystemic shunt or liver transplantation. However, further research is needed to establish optimal protocols, patient selection criteria, and long-term outcomes of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.